Beijing Tiankeya Biotechnology

Tiankeya Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of T-cell receptor engineered T-cell (TCR-T) therapies for solid tumors. The company utilizes its proprietary TRUST platform for high-throughput TCR screening and its T-MAX manufacturing system to accelerate the production of personalized and off-the-shelf cell therapies. Its lead programs target HPV-associated malignancies and KRAS mutations, with several candidates currently undergoing Phase 1 and Phase 2 clinical trials in both China and the United States. Tiankeya is dedicated to overcoming the challenges of the immunosuppressive tumor microenvironment to provide effective treatments for patients with advanced cancers.